Biobankwide association scan identifies risk factors for lateonset Alzheimer’s disease and endophenotypes
eLife assessment
In the last 15 years, largescale association studies (GWAS) have served to estimate the association between genomewide common variants and a large number of disparate traits and diseases in humans. This valuable method provides a new way to find correlations between the genetic component of a phenotype of interest, and all this wealth of genetic information. This software adds as a new tool to investigate genetic correlation between traits, and to generate new mechanistic hypotheses and dissect the role of the observed associations in disease heterogeneity. The results of the application of their method are solid and generally agree with what others have seen using similar AD and UKB data.
https://doi.org/10.7554/eLife.91360.2.sa0Valuable: Findings that have theoretical or practical implications for a subfield
 Landmark
 Fundamental
 Important
 Valuable
 Useful
Solid: Methods, data and analyses broadly support the claims with only minor weaknesses
 Exceptional
 Compelling
 Convincing
 Solid
 Incomplete
 Inadequate
During the peerreview process the editor and reviewers write an eLife Assessment that summarises the significance of the findings reported in the article (on a scale ranging from landmark to useful) and the strength of the evidence (on a scale ranging from exceptional to inadequate). Learn more about eLife Assessments
Abstract
Rich data from large biobanks, coupled with increasingly accessible association statistics from genomewide association studies (GWAS), provide great opportunities to dissect the complex relationships among human traits and diseases. We introduce BADGERS, a powerful method to perform polygenic scorebased biobankwide association scans. Compared to traditional approaches, BADGERS uses GWAS summary statistics as input and does not require multiple traits to be measured in the same cohort. We applied BADGERS to two independent datasets for lateonset Alzheimer’s disease (AD; n=61,212). Among 1738 traits in the UK biobank, we identified 48 significant associations for AD. Family history, high cholesterol, and numerous traits related to intelligence and education showed strong and independent associations with AD. Furthermore, we identified 41 significant associations for a variety of AD endophenotypes. While family history and high cholesterol were strongly associated with AD subgroups and pathologies, only intelligence and educationrelated traits predicted preclinical cognitive phenotypes. These results provide novel insights into the distinct biological processes underlying various risk factors for AD.
Introduction
Lateonset AD is a prevalent, complex, and devastating neurodegenerative disease without a current cure. Millions of people are currently living with AD worldwide, and the number is expected to grow rapidly as the population continues to age (Prince et al., 2013; Reitz and Mayeux, 2014). With the failure of numerous drug trials, it is of great interest to identify modifiable risk factors that can be potential targets in the therapeutics development for AD (Østergaard et al., 2015; Larsson et al., 2017; Norton et al., 2014). Epidemiological studies that directly test associations between measured risk factors and AD are difficult to conduct and interpret because identified associations are, in many cases, affected by confounding and reverse causality. Despite being ubiquitous challenges in risk factor studies for complex diseases, these issues are particularly critical for AD due to its extended preclinical stage – irreversible pathologic changes have already occurred in the decade or two prior to clinical symptoms (Jack et al., 2013). On the other hand, Mendelian randomization methods (Sleiman and Grant, 2010; Davey Smith and Hemani, 2014; Zhu et al., 2018) have been developed to identify causal risk factors for disease using data from GWAS. Despite the favorable theoretical properties in identifying causal relationships, these methods have limited statistical power, thereby not suitable for hypothesisfree screening of risk factors.
Motivated by transcriptomewide association study – an analysis strategy that identifies genes whose genetically regulated expression values are associated with disease (Gamazon et al., 2015; Gusev et al., 2016; Hu et al., 2018), we seek a systematic and statistically powerful approach to identify risk factors using summary association statistics from largescale GWAS. GWAS for lateonset AD has been successful, and dozens of associated loci have been identified to date (Lambert et al., 2013; Harold et al., 2009; Hollingworth et al., 2011; Naj et al., 2011; Seshadri et al., 2010; Jun et al., 2017). Although direct information on risk factors is limited in these studies, dense genotype data on a large number of samples, in conjunction with independent reference datasets for thousands of complex human traits such as the UK biobank (Bycroft et al., 2017), make it possible to genetically impute potential risk factors and test their associations with AD. This strategy allows researchers to study risk factors that are not directly measured in AD studies. Furthermore, it reduces the reverse causality because the imputation models are trained on independent, younger, and mostly dementiafree reference cohorts, thereby improving the interpretability of findings.
Here, we introduce BADGERS (Biobankwide Association Discovery using GEnetic Risk Scores), a statistically powerful and computationally efficient method to identify associations between a disease of interest and a large number of genetically imputed complex traits using GWAS summary statistics. We applied BADGERS to identify associated risk factors for AD from 1738 heritable traits in the UK biobank and replicated our findings in independent samples. Furthermore, we performed multivariate conditional analysis, Mendelian randomization, and followup association analysis with a variety of AD biomarkers, pathologies, and preclinical cognitive phenotypes to provide mechanistic insights into our findings.
Results
Method overview
Here, we briefly introduce the BADGERS model. The workflow of BADGERS is shown in Figure 1. A brief flowchart including all the analyses we contained in the manuscript was shown in the supplementary material (Figure 1—figure supplement 1). Complete statistical details are discussed in the Methods section. BADGERS is a twostage method to test associations between traits. First, polygenic risk scores (PRS) are trained to impute complex traits using genetic data. Next, we test the association between a disease or trait of interest and various geneticallyimputed traits. Given a PRS model, the imputed trait can be denoted as
where ${X}_{N\times M}$ is the genotype matrix for $N$ individuals in a GWAS, and ${W}_{M\times 1}$ is the Mx1 matrix denotes precalculated weight values on SNPs in the PRS model. Then, we test the association between measured trait $Y$ and imputed trait $\widehat{T}$ via a univariate linear model.
The test statistic for $\gamma $ can be expressed as:
where $\stackrel{~}{Z}$ is the vector of SNPlevel association zscores for trait $Y$, and $\Gamma $ is a diagonal matrix with the j^{th} diagonal element being the ratio between the standard deviation of the j^{th} SNP and that of $\hat{T}$ .
This model can be further generalized to perform multivariate analysis. If $K$ imputed traits are included in the analysis, we use a similar notation as in univariate analysis:
Here, ${W}_{M\times K}^{*}$ is a matrix and each column of ${W}^{*}$ is the precalculated weight values on SNPs for each imputed trait. Then, the associations between $Y$ and $K$ imputed traits ${\hat{T}}_{i}\phantom{\rule{thinmathspace}{0ex}}\left(1\le i\le K\right)$ are tested via a multivariate linear model.
where ${\gamma}^{*}={({\gamma}_{1},\dots ,{\gamma}_{K})}^{T}$ is the vector of regression coefficients. The zscore for ${\gamma}_{i}\left(1\le i\le K\right)$ can be denoted as:
where $U$ is the inverse variancecovariance matrix of $\hat{T}}^{\ast$ ; ${I}_{i}$ is the $K\times 1$ vector with the i^{th} element being 1 and all other elements equal to 0; is a $M\times M$ diagonal matrix with the i^{th} diagonal element being $\sqrt{var\left({X}_{i}\right)}$ ; and $\stackrel{~}{Z}$ is defined the same as the univariate case as the vector of SNPlevel association zscores for trait $Y$.
Simulations
We used real genotype data from the Genetic Epidemiology Research on Adult Health and Aging (GERA) to conduct simulation analyses (Methods). First, we evaluated the performance of our method on data simulated under the null hypothesis. We tested the associations between randomly simulated traits and 1738 PRS from the UK biobank and did not observe inflation in typeI error (Supplementary file 1). Similar results were also observed when we simulated traits that are heritable but not directly associated with any PRS. Since BADGERS only uses summary association statistics and externally estimated linkage disequilibrium (LD) as input, we also compared effect estimates in BADGERS with those of traditional regression analysis based on individuallevel data. Regression coefficient estimates and association pvalues from these two methods were highly consistent in both simulation settings (Figure 2A and Figure 2—figure supplements 1–3), showing minimal information loss in summary statistics compared to individuallevel data indicating highly consistent performance compared to methods based on individuallevel data. To evaluate the statistical power of BADGERS, we simulated traits by combining effects from randomly selected PRS and a polygenic background (Methods). We set the effect size of PRS to be 0.02, 0.015, 0.01, 0.008, and 0.005. BADGERS showed comparable statistical power to the regression analysis based on individuallevel genotype and phenotype data (Figure 2B, Supplementary file 1). Overall, our results suggest that using summary association statistics and externally estimated LD as a proxy for individuallevel genotype and phenotype data does not inflate typeI error rate or decrease power. The performance of BADGERS is comparable to regression analysis based on individuallevel data. We also studied if more sophisticated polygenic risk prediction methods could potentially lead to higher statistical power in downstream association tests. We compared the performance of PRS based on marginal effect sizes with that of LDpred, a more sophisticated PRS model that jointly estimates SNP effects via a Bayesian framework (Vilhjálmsson et al., 2015). Imputation models based on multivariate analysis indeed improved the results. When using marginal PRS to impute traits, the correlation between $\hat{\gamma}}_{i$ and $\gamma}_{i$ was 0.79. This correlation improved to 0.91 when using LDpred PRS (Figure 2—figure supplement 4). However, such improvement did not substantially affect the statistical power in association testing. Using marginal PRS, our analysis achieved a statistical power of 86% to identify associations at a typeI error rate of 0.05, and the power was 88% when using multivariate effect estimates to calculate PRS. These results suggest that while more sophisticated PRS methods can improve the results in BADGERS, simple PRS based on marginal effects also shows reasonably good performance.
Identify risk factors for lateonset AD among 1738 heritable traits in the UK biobank
We applied BADGERS to conduct a biobankwide association scan (BWAS) for AD risk factors from 1738 heritable traits (p<0.05; Methods) in the UK biobank. We repeated the analysis on two independent GWAS datasets for AD and further combined the statistical evidence via metaanalysis (Figure 3—figure supplement 1). We used stageI association statistics from the International Genomics of Alzheimer’s Project (IGAP; n=54,162) as the discovery phase, then replicated the findings using 7050 independent samples from the Alzheimer’s Disease Genetics Consortium (ADGC). We identified 50 significant traitAD associations in the discovery phase after correcting for multiple testing, among which 14 had p<0.05 in the replication analysis. Despite the considerably smaller sample size in the replication phase, top traits identified in the discovery stage showed strong enrichment for p<0.05 in the replication analysis (enrichment = 2.5, p=2.2e5; hypergeometric test). In the metaanalysis, a total of 48 traits reached Bonferronicorrected statistical significance and showed consistent effect directions in the discovery and replication analyses (Figure 3 and Supplementary file 2).
Unsurprisingly, many identified associations were related to dementia and cognition. Family history of AD and dementia showed the most significant associations with AD (p=3.7e77 and 5.2e28 for illnesses of mother and father, respectively). Having any dementia diagnosis is also strongly and positively associated (p=8.5e11). In addition, we observed consistent and negative associations between better performance in cognition test and AD risk. These traits include fluid intelligence score (p=2.4e14), time to complete round in cognition test (p=2.8e9), correct final attempt (p=9.1e11), and many others. Consistently, education attainment showed strong associations with AD. Age completed full time education (p=2.5e7) was associated with lower AD risk. Four out of seven traits based on a survey about education and qualifications were significantly associated with AD (Figure 3—figure supplement 2). Higher education such as having a university degree (p=4.4e12), A levels/AS levels or equivalent (p=6.9e9), and professional qualifications (p=7.1e6) were associated with lower AD risk. In contrast, choosing ‘none of the above’ in this survey was associated with a higher risk (p=1.6e11). Other notable strong associations include high cholesterol (p=2.5e15; positive), lifestyle traits such as cheese intake (p=2.5e10; negative), occupation traits such as job involving heavy physical work (p=2.7e10; positive), anthropometric traits including height (p=5.3e7; negative), and traits related to pulmonary function, e.g., forced expiratory volume in 1 s (FEV1; p=1.9e6; negative). Detailed information on all associations is summarized in Supplementary file 2.
Multivariate conditional analysis identifies independently associated risk factors
Of note, associations identified in the marginal analysis are not guaranteed to be independent. We observed clear correlational structures among the identified traits (Figure 4). For example, PRS of various intelligence and cognitionrelated traits are strongly correlated, and consumption of cholesterollowering medication is correlated with selfreported high cholesterol. To account for the correlations among traits and identify risk factors that are independently associated with AD, we performed multivariate conditional analysis using GWAS summary statistics (Methods). First, we applied hierarchical clustering to the 48 traits we identified in marginal association analysis and divided these traits into 15 representative clusters. The traits showing the most significant marginal association in each cluster were included in the multivariate analysis (Figure 4—figure supplement 1). Similar to the marginal analysis, we analyzed IGAP and ADGC data separately and combined the results using metaanalysis (Supplementary file 2). All 15 representative traits remained nominally significant (p<0.05) and showed consistent effect directions between marginal and conditional analyses (Supplementary file 1). However, several traits showed substantially reduced effect estimates and inflated pvalues in multivariate analysis, including fluid intelligence score, mother still alive, unable to work because of sickness or disability, duration of moderate activity, and intake of cholesterollowering spread. Interestingly, major trait categories that showed the strongest marginal associations with AD (i.e. family history, high cholesterol, and education/cognition) were independent from each other. Paternal and maternal family history also showed independent associations with AD, consistent with the low correlation between their genetic risk scores (correlation = 0.052).
Influence of the APOE region on identified associations
Furthermore, we evaluated the impact of APOE on identified associations. We removed the extended APOE region (chr19: 45,147,340–45,594,595; hg19) from summary statistics of the 48 traits showing significant marginal associations with AD and repeated the analysis. We observed a substantial drop in the significance level of many traits, especially family history of AD, dementia diagnosis, and high cholesterol (Figure 5, Figure 5—figure supplement 1, and Supplementary file 2). 38 out of 48 traits remained significant under stringent Bonferroni correction after APOE removal. Interestingly, the associations between AD and almost all cognition/intelligence traits were virtually unchanged, suggesting a limited role of APOE in these associations.
Causal inference via Mendelian randomization
Next, we investigated the evidence for causality among identified associations. We performed Mendelian randomization (MRIVW; Methods) in IGAP and ADGC datasets separately and metaanalyzed the results on the complete set of 1738 heritable traits from the UK biobank. A total of 48 traits reached Bonferronicorrected statistical significance and showed consistent effect directions in the discovery and replication analyses using BADGERS. In contrast, MRIVW only identified nine traits with Bonferronicorrected statistical significance. Among these nine traits, seven were also identified by BADGERS (Supplementary file 1). The signs of all significant causal effects identified by MRIVW were consistent with results from BADGERS. The most significant effect was family history (p=1.1e233 and 1.7e69 for maternal and paternal history, respectively). Dementia diagnosis (p=9.1e7), high cholesterol (p=4.1e6), A levels/AS levels education (p=1.7e4), and time spent watching television (p=2.4e4) were also among the top significant effects. Of note, the fluid intelligence score, one of the most significant associations identified by BADGERS, did not reach statistical significance in MR (p=0.06), which may be explained by its polygenic genetic architecture. It is also worth noting that if we scan all 1738 traits using BADGERS and then apply MRIVW on the 48 Bonferronicorrected significant traits, 23 could reach nominal significance (p<0.05) in MR, and seven could reach significance under Bonferroni correction (p<0.05/48; Supplementary file 1).
We also compared BADGERS with another more recent method GSMR (Zhu et al., 2018). Due to the smaller sample size in the ADGC dataset, we only applied GSMR to the IGAP summary statistics. In total, 18 traits reached statistical significance under Bonferroni correction (Supplementary file 1). However, these results showed only moderate consistency with MRIVW and BADGERS. Among the 18 significant traits, only 1 trait, maternal family history of Alzheimer’s disease and dementia, overlapped with significant traits identified by MRIVW. Six out of 18 traits overlapped with significant traits identified by BADGERS. Among the 18 significant traits, eight are related to body fat mass and two are related to educational attainment. The most significant effect was illnesses of mother (p=2.4e294). College or University degree (p=4.84e6), education; none of the above (p=3.6e4), A levels/AS levels education (p=3.8e6), and time spent watching television (p=4.0e3) were also among top significant effects. Notably, GSMR failed to identify paternal family history or high cholesterol as risk factors for Alzheimer’s disease. If we only consider the 48 significant traits identified by BADGERS, 11 were nominally significant (p<0.05). However, 23 traits did not have enough significant SNPs to perform the GSMR analysis (at least 10 SNPs are required). The signs of all significant causal effects identified by GSMR were consistent between association effects in BADGERS.
Additionally, we included GSMR analysis results after removing APOE region from the 48 identified traits. Only maternal family history reached Bonferronicorrected statistical significance, further demonstrating the lack of statistical power in MR when performing biobankwide scans (Supplementary file 1).
Associations with AD subgroups, biomarkers, and pathologies
To further investigate the mechanistic pathways for the identified risk factors, we applied BADGERS to a variety of AD subgroups, biomarkers, and neuropathologic features (Supplementary file 1). Overall, 29 significant associations were identified under a false discovery rate (FDR) cutoff of 0.05, and these endophenotypes showed distinct association patterns with AD risk factors (Figure 6; Figure 6—figure supplement 1). First, we tested the associations between the 48 ADassociated traits and five AD subgroups defined in the Executive Prominent Alzheimer’s Disease (EPAD) study, i.e., memory, language, visuospatial, none, and mix (Methods) (Mukherjee et al., 2018; Crane et al., 2017). Maternal family history of AD and dementia was strongly and consistently associated with all five EPAD subgroups (Supplementary file 2), with memory subgroup showing the strongest association (p=3.3e16), which is consistent with the higher frequency of APOE ε4 in this subgroup (Mukherjee et al., 2018). Paternal family history was not strongly associated with any subgroups, but the effect directions were consistent. Interestingly, intelligence and cognitionrelated traits such as correct final attempt in cognitive test (p=2.7e5) and fluid intelligence score (p=6.8e5) were specifically associated with the ‘none’ subgroup – AD samples without relative impairment in any of the four cognitive domains. High cholesterol and related traits were associated with language, memory, and mix (i.e. AD samples with relative impairment in two or more domains) subgroups but showed weaker associations with the visuospatial and none subgroups.
Next, we extended our analysis to three biomarkers of AD in cerebrospinal fluid (CSF): amyloid beta (Aβ_{42}), tau, and phosphorylated tau (ptau_{181}) (Deming et al., 2017). Somewhat surprisingly, AD risk factors did not show strong associations with Aβ_{42} and tau (Supplementary file 2). Maternal family history of AD and dementia was associated with ptau_{181} (p=4.2e4), but associations were absent for Aβ_{42} and tau. It has been recently suggested that CSF biomarkers have a sexspecific genetic architecture (Deming et al., 2018). However, no association passed an FDR cutoff of 0.05 in our sexstratified analyses (Supplementary file 2).
Furthermore, we applied BADGERS to a variety of neuropathologic features of AD and related dementias (Methods), including neuritic plaques (NPs), neurofibrillary tangles (NFTs), cerebral amyloid angiopathy (CAA), lewy body disease (LBD), hippocampal sclerosis (HS), and vascular brain injury (VBI) (Beecham et al., 2014). Family history of AD/dementia (p=3.8e8, maternal; p=1.4e5, paternal) and high cholesterol (p=2.1e5) were strongly associated with NFT Braak stages (Supplementary file 2). NP also showed very similar association patterns with these traits (p=2.7e19, maternal family history; p=2.6e7, paternal family history; p=0.001, high cholesterol). The other neuropathologic features did not show strong associations. Of note, despite not being statistically significant, family history of AD/dementia was negatively associated with VBI, and multiple intelligence traits were positively associated with LBD, showing distinct patterns with other pathologies (Figure 6—figure supplement 2). We also note that various versions of the same pathologies all showed consistent associations in our analyses (Figure 6—figure supplement 2). The complete association results for all the endophenotypes and all the traits are summarized in Supplementary file 2. We further identified the influence of the APOE region in these results. The association results for all the endophenotypes with APOE Region being removed are summarized in Supplementary file 2.
Associations with cognitive traits in a preclinical cohort
Finally, we studied the associations between AD risk factors and preclinical cognitive phenotypes using 1198 samples from the Wisconsin Registry for Alzheimer’s Prevention (WRAP), a longitudinal study of initially dementiafree middleaged adults (Johnson et al., 2018). Assessed phenotypes include mild cognitive impairment (MCI) status and three cognitive composite scores for executive function, delayed recall, and learning (Methods). A total of 12 significant associations reached an FDR cutoff of 0.05 (Supplementary file 2). Somewhat surprisingly, parental history and high cholesterol, the risk factors that showed the strongest associations with various AD endophenotypes, were not associated with MCI or cognitive composite scores in WRAP. Instead, education and intelligencerelated traits strongly predicted preclinical cognition (Figure 7). Alevels education and no education both showed highly significant associations with delayed recall (p=4.0e5 and 7.7e7) and learning (p=7.6e6 and 5.0e8). No education was also associated with higher risk of MCI (p=2.5e4). Additionally, fluid intelligence score was positively associated with the learning composite score (p=7.5e4), and time to complete round in cognition test was negatively associated with the executive function (p=1.1e5).
Discussion
In this work, we introduced BADGERS, a new method to perform association scans at the biobank scale using genetic risk scores and GWAS association statistics. Through simulations, we demonstrated that our method provides consistent effect estimates and similar statistical power compared to regression analysis based on individuallevel data. Additionally, we applied BADGERS to two large and independent GWAS datasets for lateonset AD. In our analyses, we used GWAS summary statistics from the UK biobank, one of the largest genetic cohort in the world, to generate PRS for complex traits. We estimated heritability for all available traits in the UK biobank and only included traits with nominally significant heritability (p<0.05) in our analyses. The GWAS summary statistics for Alzheimer’s disease were also obtained from the largest available study – International Genomics of Alzheimer’s Project (IGAP) and we further sought replication using a large, independent dataset from the Alzheimer’s Disease Genetics Consortium (ADGC). Overall, we are confident that these quality control procedures largely controlled the false findings in our study. Among 1738 heritable traits in the UK biobank, we identified 48 traits showing statistically significant associations with AD. These traits covered a variety of categories, including family history, cholesterol, intelligence, education, occupation, and lifestyle. Although many of the identified traits are genetically correlated, multivariate conditional analysis confirmed multiple strong and independent associations for AD. Family history showing strong associations with AD is not a surprise, and many other associations are supported by the literature as well. The protective effect of higher educational and occupational attainment on the risk and onset of dementia is well studied (Valenzuela and Sachdev, 2006; Stern, 2012). Cholesterol buildup is also known to associate with βamyloid plaques in the brain and higher AD risk (Reed et al., 2014; Djelti et al., 2015; Simons et al., 2001).
More interestingly, these identified traits had distinct association patterns with various AD subgroups, biomarkers, pathologies, and preclinical cognitive traits. Five cognitivelydefined AD subgroups were consistently associated with maternal family history, but only the group without substantial relative impairment in any domain (i.e. EPAD_none) was associated with intelligence and education. In addition, family history and high cholesterol were strongly associated with classic AD neuropathologies, including NP and NFT, while intelligence and educational attainment predicted preclinical cognitive scores and MCI. These results suggest that various AD risk factors may affect the disease course at different time points and via distinct biological processes, and genetically predicted risk factors for clinical AD include at least two separate components. While some risk factors (e.g. high cholesterol and APOE) may directly contribute to the accumulation of pathologies, other factors (e.g. intelligence and education) may buffer the adverse effect of brain pathology on cognition (Stern, 2012). One possible scenario is that family history and high cholesterol are the fundamental causes of AD while education level and intelligence are the parameters of such factors. While if one didn’t have such a factor in the first stage, they are protected from getting AD, if someone with such factor and also has high score in education attainment or intelligence, they can also get rid of the possibility of getting AD. We also investigated the influence of APOE on the identified associations. Effects of family history and high cholesterol were substantially reduced after APOE removal. In contrast, associations with cognition and education were virtually unchanged. These results suggest that various AD risk factors may affect the disease course at different time points and via distinct biological processes. While some risk factors (e.g. high cholesterol and APOE) may directly contribute to the accumulation of pathologies, other factors (e.g. intelligence and education) reduce the adverse effect of brain pathology on cognition (Stern, 2012).
Furthermore, we note that the association results in BADGERS need to be interpreted with caution. Although PRSbased association analysis is sometimes treated as causal inference in the literature (Paternoster et al., 2017), we do not see BADGERS as a tool to identify causal factors. Key assumptions in causal inference are in many cases, violated when analyzing complex, highly polygenic traits, which may lead to complications when interpreting results. In our analysis, BADGERS showed superior statistical power than MRIVW – among 1738 heritable traits, 48 reached Bonferroni significance in BADGERS, 9 and 18 traits reached Bonferroni significance in MRIVW and GSMR, respectively. Among the 48 traits identified by BADGERS, 23 reached nominal statistical significance in MRIVW and 11 were nominally significant in GSMR. BADGERS is a statistically powerful and computationally efficient method for identifying associations between a disease of interest and genetically imputed complex traits. Due to the capability of utilizing PRS with a large number of SNPs to impute complex traits, BADGERS has substantially improved statistical power compared to MR methods. And because of this, it can serve as a hypothesisfree method to screen for candidate risk factors from biobankscale datasets with an overwhelming number of traits. After a list of candidate risk factors is identified using BADGERS, MR methods can be applied to carefully demonstrate causality. We envision BADGERS as a tool to prioritize associations among a large number of candidate risk factors so that robust causal inference methods can be applied to carefully assess causal effects. In addition, BADGERS requires a reference panel to provide LD estimates as a summary statisticsbased method. If the population in the reference panel does not match that of the GWAS, it may create bias in the analysis. Our simulation results suggest that 1000 Genomes European samples is sufficient for our analysis when the GWAS was also conducted on European samples. Our implemented BADGERS software is flexible on the choice of LD reference panel. It allows users to change the reference dataset when they see fit.
What’s more, environmental factors may play a big role in the identified associations. There is little doubt that the environment could influence many complex traits, including the ones highlighted by the reviewer. However, this does not necessarily mean that these traits cannot also have a genetic component (or be genetically heritable). we summarized the heritability estimates for the 48 traits identified in our BADGERS metaanalysis of two independent datasets for Alzheimer’s disease (Supplementary file 1), and all of them have nominally significant heritability estimates (p<0.05) based on our selection criteria. Nevertheless, we do acknowledge that the high heritability of these traits is influenced by correlations with other traits. For example, job involving heavy manual or physical work is genetically correlated with educational attainment (Figure 3), which indicates that the association between this trait and Alzheimer’s disease may not be direct. Therefore, it is important to note that association results from BADGERS analysis need to be interpreted with caution.
Limited sample size in AD endophenotypes is another limitation in our study. We have used data from the largest available GWAS for CSF biomarkers and neuropathologies. Still, the small sample size made it challenging to assess the effects of traits that were weakly associated with AD. When an independent validation dataset is available, it would be of interest to assess the prediction accuracy of PRS on each trait. However, external validation datasets rarely exist in real applications. In that case, the users may choose to use heritability estimates to filter traits with a substantial genetic component. Furthermore, in the BADGERS framework, PRS are independent variables in the regression analysis. If the PRS has limited predictive power, such noise is similar to measurement errors in standard regression analysis. This may decrease the statistical power in association tests but does not inflate the typeI error rate. Finally, emerging evidence has highlighted the sexspecific genetic architecture of AD (Deming et al., 2018; Hohman et al., 2018). In our analysis, maternal family history of AD showed stronger associations with various phenotypes than paternal family history. However, we note that this may be explained by the sample size difference in the UK biobank (N_{case} = 28,507 and 15,022 for samples with maternal and paternal family history, respectively). We also performed sexstratified analyses for CSF biomarkers but identified limited associations, possibly due to the small sample size. Overall, sexspecific effects of risk factors remain to be investigated in the future using larger datasets. In total, BADGERS requires the training data for genetic prediction models and the downstream disease GWAS to be independent but of similar genetic ancestry. Development of methods that are more robust to sample overlap and diverse genetic ancestry remains an open problem for future research.
In conclusion, BADGERS is a statistically powerful method to identify associated risk factors for complex diseases. Largescale biobanks continue to provide rich data on various human traits that may be of interest in disease research. Our method uses GWAS to bridge large biobanks with studies on specific diseases, lessens the limitation of insufficient disease cases in biobanks and lack of risk factor measurements in disease studies, and provides a statistically justified approach to identifying risk factors for disease. We have demonstrated the effectiveness of BADGERS through extensive simulations, a twostage BWAS for lateonset AD, and various followup analyses on identified risk factors. Our results provided new insights into the genetic basis of AD, and revealed distinct mechanisms for the involvement of risk factors in AD etiologies. The evergrowing sample size in GWAS and biobanks, in conjunction with increasingly accessible summary association statistics, makes BADGERS a powerful and valuable tool in human genetics research.
Methods
BADGERS framework
The goal of this method is to study the association between $Y$, a measured trait in the study, and $\hat{T}$ , a trait imputed from genetic data via a linear prediction model:
Here, ${X}_{N\times M}$ is the genotype matrix for $N$ individuals in a study of trait $Y$. ${W}_{M\times 1}$ is the precalculated weight values on SNPs in the imputation model. $M$ denotes the number of SNPs. We use $Y$, a $N\times 1$ vector, to denote the trait values measured on the same group of individuals. We test the association between $Y$ and $\hat{T}$ via a linear model.
where $\alpha $ is the intercept, $\delta $ is the term for random noise, and regression coefficient $\gamma $ is the parameter of interest. The ordinary least squares (OLS) estimator for $\gamma $ can be denoted as,
Here, ${X}_{j}$ is the j^{th} column of $X$. Additionally, we derive the formula for the standard error of $\hat{\gamma}$ :
The approximation in this formula is based on the assumption that trait $Y$ has complex etiology and imputed trait $\hat{T}$ only explains a small proportion of its phenotypic variance. When an accurate estimate of $var\left(\delta \right)$ is difficult to obtain, this approximation approach provides conservative results and controls typeI error in the analysis.
In practice, individuallevel genotype (i.e. $X$) and phenotype data (i.e. $Y$) may not be accessible due to policy and privacy concerns. Therefore, it is of practical interest to perform the aforementioned association analysis using summary association statistics. Standard genetic association analysis tests the association between trait $Y$ and each SNP via the following linear model:
The OLS estimator for ${\beta}_{j}$ and its standard error have the following forms.
Again, the approximation is based on the empirical observation in complex trait genetics – each SNP explains little variability of $Y$ (Manolio et al., 2009).
Next, we derive the test statistic (i.e. zscore) for $\gamma $:
where $\Gamma $ is a diagonal matrix with the j^{th} diagonal element being
and $\stackrel{\sim}{Z}$ is the vector of SNPlevel zscores obtained from the GWAS of trait $Y$, i.e.,
Without access to individuallevel genotype data, $var\left({X}_{j}\right)$ and $var(\hat{T})$ need to be estimated using an external panel with a similar ancestry background. We use $\stackrel{~}{X}$ to denote the genotype matrix from an external cohort, then $var\left({X}_{j}\right)$ can be approximated using the sample variance of ${\stackrel{~}{X}}_{j}$ . Variance of $\hat{T}$ can be approximated as follows
where $\stackrel{~}{D}$ is the variancecovariance matrix of all SNPs estimated using $\stackrel{~}{X}$ . However, when the number of SNPs is large in the imputation model for trait $T$, calculation of $\stackrel{~}{D}$ is computationally intractable. Instead, we use an equivalent but computationally more efficient approach. We first impute trait $T$ in the external panel using the same imputation model
Then, $var(\hat{T})$ can be approximated by sample variance $var(\stackrel{\sim}{T})$ .
Thus, we can test the association between $Y$ and $\hat{T}$ without having access to individuallevel genotype and phenotype data from the GWAS. The required input variables for BADGERS include a linear imputation model for trait $T$, SNPlevel summary statistics from a GWAS of trait $Y$, and an external panel of genotype data. With these, the association test can be performed.
Multivariate analysis in BADGERS
To adjust for potential confounding effects, it may be of interest to include multiple imputed traits in the same BADGERS model. We still use $Y$ to denote the measured trait of interest. The goal is to perform a multiple regression analysis using $K$ imputed traits (i.e. $\hat{T}}_{1$ ,..., $\hat{T}}_{K$) as predictor variables:
Here, we use ${\hat{T}}^{\ast}=({\hat{T}}_{1},\dots ,{\hat{T}}_{K})$ to denote a $N\times K$ matrix for $K$ imputed traits. Regression coefficients ${\gamma}^{*}={({\gamma}_{1},\dots ,{\gamma}_{K})}^{T}$ are the parameters of interest. To simplify algebra, we also assume trait $Y$ and all SNPs in the genotype matrix $X$ are centered so there is no intercept term in the model, but the conclusions apply to the general setting. Similar to univariate analysis, traits $\hat{T}}_{1},\dots ,{\hat{T}}_{K$ are imputed from genetic data via linear prediction models:
where ${W}_{M\times K}^{*}$ are imputation weights assigned to SNPs. The i^{th} column of $W$ denotes the imputation model for trait ${T}_{i}$ . Then, the OLS estimator $\hat{\gamma}}^{\ast$ and its variancecovariance matrix can be denoted as follows:
The approximation is based on the assumption that imputed traits $\hat{T}}_{1},\dots ,{\hat{T}}_{K$ collectively explain little variance in $Y$, which is reasonable in complex trait genetics if $K$ is not too large. We further denote:
All elements in matrix $U$ can be approximated using a reference panel $\stackrel{~}{X}$ (Dudbridge, 2013):
Therefore, the zscore for ${\gamma}_{k}\left(1\le k\le K\right)$ is
where ${I}_{k}$ is the $K\times 1$ vector with the k^{th} element being 1 and all other elements equal to 0, is a $M\times M$ diagonal matrix with the i^{th} diagonal element being $\sqrt{var\left({X}_{i}\right)}$ , and similar to the notation in univariate analysis, $\stackrel{~}{Z}$ is the vector of SNPlevel zscores from the GWAS of trait $Y$. Given imputation models for $K$ traits (i.e. ${W}^{*}$), GWAS summary statistics for trait $Y$ (i.e. $\stackrel{~}{Z}$), and an external genetic dataset to estimate $U$ and , multivariate association analysis can be performed without genotype and phenotype data from the GWAS.
Genetic prediction
Any linear prediction model can be used in the BADGERS framework. With access to individuallevel genotype and phenotype data, the users can train their preferred statistical learning models, e.g., penalized regression or linear mixed model. When only GWAS summary statistics are available for risk factors (i.e. $T$), PRS can be used for imputation. We used PRS to impute complex traits in all analyses throughout the paper. Of note, more advanced PRS methods that explicitly model LD (Vilhjálmsson et al., 2015) and functional annotations (Hu et al., 2017) to improve prediction accuracy have been developed. However, additional independent datasets may be needed if there are tuning parameters in PRS. In general, higher imputation accuracy will improve statistical power in association testing (Hu et al., 2018). The BADGERS software allows users to choose their preferred imputation model.
Simulation settings
We simulated quantitative traits using genotype data of 62,313 individuals from the GERA cohort (dbGap accession: phs000674). Summary association statistics were generated using PLINK (Purcell et al., 2007). We ran BADGERS on summary statistics based on the simulated traits and PRS of 1738 traits in the UK biobank. To compare BADGERS with the traditional approach that uses individuallevel data as input, we also directly regressed simulated traits on the PRS of UK biobank traits to estimate association effects.
Setting 1
We simulated quantitative trait values as i.i.d. samples from normal distribution with mean 0 and variance 1. In this setting, simulated trait values were independent from genotype data.
Setting 2
We simulated quantitative trait values based on an additive random effect model commonly used in heritability estimation (Yang et al., 2015). We fixed heritability to be 0.1. In this setting, the simulated trait is associated with SNPs, but is not directly related to PRS of UK biobank traits.
Setting 3
We selected 100 traits from 1738 UKBiobank traits to calculate PRS on GERA data. For each of these 100 PRS, we simulated a quantitative trait by summing up the effect of PRS, a polygenic genetic background, and a noise term.
Here, $X$ denotes the genotype of samples; $\beta $ is the effect size of each variant; $P$ is the PRS of one of the selected traits; $\rho $ is the effect size of PRS; and $\epsilon $ is the error term following a standard normal distribution. The polygenic background and random noise (i.e. $X\beta +\epsilon $) were simulated using the same model described in setting 2. This term and the PRS were normalized separately. The standardized effect size (i.e. $\rho $) was set as 0.02, 0.015, 0.01, 0.008, and 0.005 in our simulations. In this setting, simulated traits are directly associated with SNPs and PRS. For each value of $\rho $, statistical power was calculated as the proportion of significant results (p<0.05) out of 100 traits.
Setting 4
We simulated 100 quantitative traits $T}_{1},\dots ,{T}_{100$ based on an additive random effect model commonly used with heritability fixed as 0.1. And the response traits $Y}_{1},\dots ,{Y}_{100$ were simulated by adding a noise term to $T.$
Where ${\gamma}_{i}\sim N\left(0,2\right)$ , and ${\epsilon}_{i}\sim N\left(0,Var\left({T}_{i}\right)\right).$ The dataset was split into two subsets, one with 31,162 (subset 1) and another with 31,163 samples (subset 2). Marginal summary statistics correspond to ${T}_{i}$ ’s and ${Y}_{i}$ ’s were derived using subset 1 and subset 2, respectively. We applied LDpred to jointly estimate all SNPs’ effects using marginal summary statistics from subset 1. Then, we ran BADGERS to identify associations between 100 pairs of ${Y}_{i}$ and ${T}_{i}$ using two methods to impute ${T}_{i}$ ’s (i.e. marginal PRS and LDpred).
GWAS datasets
Summary statistics for 4357 UK biobank traits were generated by Dr. Benjamin Neale’s group and were downloaded from (http://www.nealelab.is/ukbiobank). AD summary statistics from the IGAP stageI analysis were downloaded from the IGAP website (http://web.pasteurlille.fr/en/recherche/u744/igap/igap_download.php). ADGC phase 2 summary statistics were generated by first analyzing individual datasets using logistic regression adjusting for age, sex, and the first three principal components in the program SNPTest v2 (Marchini et al., 2007). Metaanalysis of the individual dataset results was then performed using the inversevariance weighted approach (Willer et al., 2010).
GWAS summary statistics for neuropathologic features of AD and related dementias were obtained from the ADGC. Details on these data have been previously reported (Beecham et al., 2014). We analyzed a total of 13 neuropathologic features, including four NP traits, two traits for NFT Braak stages, three traits for LBD, CAA, HS, and two VBI traits. Among different versions of the same pathology, we picked one dataset for each pathologic feature to show in our primary analyses. Six AD subgroups were defined in the recent EPAD paper (Mukherjee et al., 2018) on the basis of relative performance in memory, executive functioning, visuospatial functioning, and language at the time of Alzheimer’s diagnosis. Four subgroups include AD samples with an isolated substantial relative impairment in one of four domains; the ‘none’ subgroup includes samples without substantial relative impairment; the ‘mix’ subgroup includes samples with relative impairment in multiple domains. Each domain was compared with healthy controls in casecontrol association analyses. We did not include the executive functioning subgroup in our analysis due to its small sample size in cases. Detailed information about the design of CSF biomarker GWAS and the recent sexstratified analysis has been described previously (Deming et al., 2017; Deming et al., 2018). Details on the association statistics for AD subgroups, CSF biomarkers, and neuropathological features are summarized in Supplementary file 2.
Analysis of GWAS summary statistics
We applied LD score regression implemented in the LDSC software (BulikSullivan et al., 2015) to estimate the heritability of each trait. Among 4357 traits, we selected 1738 with nominally significant heritability (p<0.05) to include in our analyses. We removed SNPs with association pvalues greater than 0.01 from each of the 1738 summary statistics files, clumped the remaining SNPs using a LD cutoff of 0.1 and a radius of 1 Mb in PLINK (Purcell et al., 2007), and built PRS for each trait using the effect size estimates of remaining SNPs.
Throughout the paper, we used samples of European ancestry in the 1000 Genomes Project as a reference panel to estimate LD (Abecasis et al., 2012). In univariate analyses, we tested marginal associations between each PRS and AD using the IGAP stageI dataset and replicated the findings using the ADGC summary statistics. Association results in two stages were combined using an inverse varianceweighted metaanalysis (Willer et al., 2010). A stringent Bonferronicorrected significance threshold was used to identify ADassociated risk factors. For associations between identified risk factors and AD endophenotypes, we used an FDR cutoff of 0.05 to claim statistical significance. We applied hierarchical clustering to the covariance of 48 traits we identified from marginal association analysis, then divided the result into 15 clusters and selected one most significant trait from each cluster and used them to perform multivariate conditional analysis. We analyzed IGAP and ADGC datasets separately, and combined the results using metaanalysis.
We used MRIVW approach (Burgess et al., 2013) implemented in the Mendelian Randomization R package (Yavorska and Burgess, 2017) to study the causal effects of 48 risk factors identified by BADGERS. For each trait, we selected instrumental SNP variables as the top 30 most significant SNPs after clumping all SNPs using a LD cutoff of 0.1.
Analysis of WRAP data
WRAP is a longitudinal study of initially dementiafree middleaged adults that allows for the enrollment of siblings and is enriched for a parental history of AD. Details of the study design and methods used have been previously described (Johnson et al., 2018; Sager et al., 2005). After quality control, a total of 1198 participants whose genetic ancestry was primarily of European descent were included in our analysis. On average, participants were 53.7 years of age (SD = 6.6) at baseline and had a bachelor’s degree, and 69.8% (n=836) were female. Participants had two to six longitudinal study visits, with an average of 4.3 visits, leading to a total of 5184 observations available for analysis.
DNA samples were genotyped using the Illumina MultiEthnic Genotyping Array at the University of Wisconsin Biotechnology Center. Thirtysix blinded duplicate samples were used to calculate a concordance rate of 99.99%, and discordant genotypes were set to missing. Imputation was performed with the Michigan Imputation Server v1.0.3 (Das et al., 2016), using the Haplotype Reference Consortium (HRC) v. r1.1 2016 (McCarthy et al., 2016) as the reference panel and Eagle2 v2.3 (Loh et al., 2016) for phasing. Variants with a quality score R^{2} <0.80, MAF <0.001, or that were out of HWE were excluded, leading to 10,499,994 imputed and genotyped variants for analyses. Data cleaning and file preparation were completed using PLINK v1.9 (Chang et al., 2015) and VCFtools v0.1.14 (Danecek et al., 2011). Coordinates are based on the hg19 genome build. Due to the sibling relationships present in the WRAP cohort, genetic ancestry was assessed and confirmed using Principal Components Analysis in Related Samples (PCAiR), a method that makes robust inferences about population structure in the presence of relatedness (Conomos et al., 2015).
Composite scores were calculated for executive function, delayed recall, and learning based on a previous analysis (Clark et al., 2016). Each composite score was calculated from three neuropsychological tests, which were each converted to zscores using baseline means and standard deviations. These zscores were then averaged to derive executive function and delayed recall composite scores at each visit for each individual. Cognitive impairment status was determined based on a consensus review by a panel of dementia experts. Resulting cognitive statuses included cognitively normal, early MCI, clinical MCI, impairment that was not MCI, or dementia, as previously defined (Koscik et al., 2016). Participants were considered cognitively impaired if their worst consensus conference diagnosis was early MCI, clinical MCI, or dementia (n=387). Participants were considered cognitively stable if their consensus conference diagnosis was cognitively normal across all visits (n=803).
The 48 PRSs were developed within the WRAP cohort using PLINK v1.9 (Chang et al., 2015) and tested for associations with the three composite scores (i.e. executive function, delayed recall, and learning) and cognitive impairment statuses. MCI status was tested using logistic regression models in R, while all other associations, which utilized multiple study visits, were tested using linear mixed regression models implemented in the lme4 package in R (Bates et al., 2015). All models included fixed effects for age and sex, and cognitive composite scores additionally included a fixed effect for practice effect (using visit number). Mixed models included random intercepts for withinsubject correlations due to repeated measures and withinfamily correlations due to the enrollment of siblings.
Software availability
The BADGERS software is freely available at https://github.com/qlulab/BADGERS, copy archived at qlulab, 2024.
Data availability
The current manuscript is a computational study, so no data have been generated for this manuscript. The modeling code is available at https://github.com/qlulab/BADGERS, copy archived at qlulab, 2024.

NIAGADS databaseID ng00036. NG00036  IGAP Summary Statistics Lambert et al. (2013).

NIAGADS databaseID NG00027. Alzheimer's Disease Genetics Consortium (ADGC) Collection.
References

Fitting linear mixedeffects models using lme4Journal of Statistical Software 67:1–48.https://doi.org/10.18637/jss.v067.i01

Mendelian randomization analysis with multiple genetic variants using summarized dataGenetic Epidemiology 37:658–665.https://doi.org/10.1002/gepi.21758

The variant call format and VCFtoolsBioinformatics 27:2156–2158.https://doi.org/10.1093/bioinformatics/btr330

Nextgeneration genotype imputation service and methodsNature Genetics 48:1284–1287.https://doi.org/10.1038/ng.3656

Mendelian randomization: genetic anchors for causal inference in epidemiological studiesHuman Molecular Genetics 23:R89–R98.https://doi.org/10.1093/hmg/ddu328

Sexspecific genetic predictors of Alzheimer’s disease biomarkersActa Neuropathologica 136:857–872.https://doi.org/10.1007/s0040101818814

Leveraging functional annotations in genetic risk prediction for human complex diseasesPLOS Computational Biology 13:e1005589.https://doi.org/10.1371/journal.pcbi.1005589

Transethnic genomewide scan identifies novel Alzheimer’s disease lociAlzheimer’s & Dementia 13:727–738.https://doi.org/10.1016/j.jalz.2016.12.012

Intraindividual cognitive variability in middle age predicts cognitive impairment 810 years later: Results from the wisconsin registry for alzheimer’s preventionJournal of the International Neuropsychological Society 22:1016–1025.https://doi.org/10.1017/S135561771600093X

Referencebased phasing using the Haplotype Reference Consortium panelNature Genetics 48:1443–1448.https://doi.org/10.1038/ng.3679

A reference panel of 64,976 haplotypes for genotype imputationNature Genetics 48:1279–1283.https://doi.org/10.1038/ng.3643

PLINK: a tool set for wholegenome association and populationbased linkage analysesAmerican Journal of Human Genetics 81:559–575.https://doi.org/10.1086/519795

Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkersBiochemical Pharmacology 88:640–651.https://doi.org/10.1016/j.bcp.2013.12.024

Middleaged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s PreventionJournal of Geriatric Psychiatry and Neurology 18:245–249.https://doi.org/10.1177/0891988705281882

Mendelian randomization in the era of genomewide association studiesClinical Chemistry 56:723–728.https://doi.org/10.1373/clinchem.2009.141564

Cognitive reserve in ageing and Alzheimer’s diseaseThe Lancet. Neurology 11:1006–1012.https://doi.org/10.1016/S14744422(12)701916

Brain reserve and dementia: a systematic reviewPsychological Medicine 36:441–454.https://doi.org/10.1017/S0033291705006264

Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk ScoresAmerican Journal of Human Genetics 97:576–592.https://doi.org/10.1016/j.ajhg.2015.09.001

MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized dataInternational Journal of Epidemiology 46:1734–1739.https://doi.org/10.1093/ije/dyx034
Article and author information
Author details
Funding
National Center for Advancing Translational Sciences (Clinical and Translational Science Award (CTSA) program, UL1TR000427)
 Bowen Hu
 Yunling Wang
 Qiongshi Lu
 Donghui Yan
U.S. National Library of Medicine (Computation and Informatics in Biology and Medicine Training Program, NLM 5T15LM007359)
 Burcu F Darst
National Institutes of Health (R01AG054047)
 Corinne D Engelman
 Qiongshi Lu
National Institutes of Health (R01AG27161)
 Sterling C Johnson
National Institutes of Health (UL1TR000427)
 Burcu F Darst
National Institutes of Health (P2C HD047873)
 Corinne D Engelman
NIH/NIA (U01 AG032984)
 Alzheimer’s Disease Genetics Consortium (ADGC)
NIH/NIA (U01 AG016976)
 Alzheimer’s Disease Genetics Consortium (ADGC)
NIH/NIA (U01 AG016976)
 Alzheimer’s Disease Genetics Consortium (ADGC)
Alzheimer’s Association (ADGC–10–196,728)
 Alzheimer’s Disease Genetics Consortium (ADGC)
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
This project was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. Support for this research was also provided by the University of WisconsinMadison Office of the Chancellor and the Vice Chancellor for Research and Graduate Education with funding from the Wisconsin Alumni Research Foundation. BFD was supported by an NLM training grant to the Computation and Informatics in Biology and Medicine Training Program [NLM 5T15LM007359]. This research was also supported by the NIH [grants R01AG054047, R01AG27161, UL1TR000427, and P2C HD047873], Helen Bader Foundation, Northwestern Mutual Foundation, Extendicare Foundation, and the State of Wisconsin. The authors thank the University of Wisconsin Madison Biotechnology Center Gene Expression Center for providing Illumina Infinium genotyping services. We thank the International Genomics of Alzheimer’s Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the subjects and their families. The iSelect chips were funded by the French National Foundation on Alzheimer’s disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2, and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer’s Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z), and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01–AG–12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer’s Association grant ADGC–10–196,728. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible; Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24AG04168901). We are also grateful for ADGC and its investigators for providing GWAS summary statistics for various AD phenotypes. The full acknowledgement to ADGC is included in the Supplementary file 1.
Version history
 Sent for peer review:
 Preprint posted:
 Reviewed Preprint version 1:
 Version of Record published:
Cite all versions
You can cite all versions using the DOI https://doi.org/10.7554/eLife.91360. This DOI represents all versions, and will always resolve to the latest one.
Copyright
© 2023, Yan, Hu et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics

 571
 views

 44
 downloads

 8
 citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading

 Epidemiology and Global Health
 Genetics and Genomics
Alzheimer’s disease (AD) is a complex degenerative disease of the central nervous system, and elucidating its pathogenesis remains challenging. In this study, we used the inversevariance weighted (IVW) model as the major analysis method to perform hypothesisfree Mendelian randomization (MR) analysis on the data from MRC IEU OpenGWAS (18,097 exposure traits and 16 AD outcome traits), and conducted sensitivity analysis with six models, to assess the robustness of the IVW results, to identify various classes of risk or protective factors for AD, earlyonset AD, and lateonset AD. We generated 400,274 data entries in total, among which the major analysis method of the IVW model consists of 73,129 records with 4840 exposure traits, which fall into 10 categories: Disease, Medical laboratory science, Imaging, Anthropometric, Treatment, Molecular trait, Gut microbiota, Past history, Family history, and Lifestyle trait. More importantly, a freely accessed online platform called MRAD (https://gwasmrad.com/mrad/) has been developed using the Shiny package with MR analysis results. Additionally, novel potential AD therapeutic targets (CD33, TBCA, VPS29, GNAI3, PSME1) are identified, among which CD33 was positively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. TBCA and VPS29 were negatively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. GNAI3 and PSME1 were negatively associated with the main outcome traits of AD, as well as with LOAD, but had no significant causal association with EOAD. The findings of our research advance our understanding of the etiology of AD.

 Chromosomes and Gene Expression
 Genetics and Genomics
Annotation of newly sequenced genomes frequently includes genes, but rarely covers important noncoding genomic features such as the cisregulatory modules—e.g., enhancers and silencers—that regulate gene expression. Here, we begin to remedy this situation by developing a workflow for rapid initial annotation of insect regulatory sequences, and provide a searchable database resource with enhancer predictions for 33 genomes. Using our previously developed SCRMshaw computational enhancer prediction method, we predict over 2.8 million regulatory sequences along with the tissues where they are expected to be active, in a set of insect species ranging over 360 million years of evolution. Extensive analysis and validation of the data provides several lines of evidence suggesting that we achieve a high truepositive rate for enhancer prediction. One, we show that our predictions target specific loci, rather than random genomic locations. Two, we predict enhancers in orthologous loci across a diverged set of species to a significantly higher degree than random expectation would allow. Three, we demonstrate that our predictions are highly enriched for regions of accessible chromatin. Four, we achieve a validation rate in excess of 70% using in vivo reporter gene assays. As we continue to annotate both new tissues and new species, our regulatory annotation resource will provide a rich source of data for the research community and will have utility for both smallscale (single gene, single species) and largescale (many genes, many species) studies of gene regulation. In particular, the ability to search for functionally related regulatory elements in orthologous loci should greatly facilitate studies of enhancer evolution even among distantly related species.